Moreover, the response to MTHFD2 suppression seemed to be higher for those AML patients with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) mutations. This evidence concerns the gene MTHFD2 and acute myeloid leukemia.